Let Velocity Solutions help you support members and small businesses during the COVID-19 crisis

first_imgOn March 26, 2020, the five primary federal financial regulators issued a joint statement encouraging banks, savings associations and credit unions to offer responsible small-dollar loans to consumers and small businesses in response to COVID-19.  The statement from the Federal Reserve, Consumer Financial Protection Bureau (CFPB), Federal Deposit Insurance Corporation (FDIC), Office of the Comptroller of the Currency (OCC) and National Credit Union Administration (NCUA) recognizes that responsible small-dollar loans can play an important role in meeting consumers’ credit needs because of temporary cash-flow imbalances, unexpected expenses, or income disruptions during periods of economic stress or disaster recoveries.In response to the coronavirus crisis, Velocity Solutions is extending a special offer to credit unions to allow you to serve your members and small businesses who need liquidity during this time of financial unrest. Velocity Solutions will implement CashPlease®, our small-dollar consumer loan platform or Akouba™, our small business loan platform on an expedited basis and will provide a one-time discount and special terms to make it easier and lower-risk for credit unions that would like to try either program.Your members and community small businesses need your support now more than ever during this unprecedented crisis. To learn more about Velocity’s CashPlease® and Akouba™ solutions and to take advantage of this special offer, please visit: https://myvelocity.com/covid19 3SHARESShareShareSharePrintMailGooglePinterestDiggRedditStumbleuponDeliciousBufferTumblrlast_img read more

Support grows for euthanasia

first_imgDominion Post 14 Sep 2012Almost 63 per cent of New Zealanders support proposed law changes that would allow ill people to end their lives, a new poll shows.Today’s results come a day after after Auckland man Evans Mott, 61, was discharged without conviction for assisting his wife to commit suicide.Labour MP Maryan Street has drafted a member’s bill that would make it legal for people who were terminally ill or suffering from an irreversible disease, to take their own life or have someone help them to die.The bill has to be drawn from the member’s ballot before it will be debated in Parliament and that could take some time.A Horizon Research poll released today found 62.9 per cent of respondents supported the move, 12.3 per cent were opposed.The poll involved 2969 adults who self-selected to participate online between July 5 and 20.It has a margin of error of 1.8 per cent.“Watching mom [sic] nurse dad to the end at our home was enough to make up my mind that at some point ending it faster is a kindness,” one respondent wrote.Men were slightly more likely to be opposed (14.2 per cent) to the law change than women (12.2 per cent) while the level of support was reasonably even between the sexes at 62.6 and 63.1 per cent respectively.There was also majority support amongst ethnicities with 65 per cent of Maori, Pakeha and Indian people supporting it, 61.5 per cent of Pacific Islanders and 55.3 per cent of Asian people.Support was particularly high among respondents aged 45-54 (71.6 per cent ) and 55-64 (65.3 per cent).The majority of people (66.9 per cent) also supported the introduction of End of Life Directives – legal documents that outline a person’s wish for medically assisted death should the issue arisehttp://www.stuff.co.nz/national/politics/7678617/Support-grows-for-euthanasialast_img read more

University of California CRISPR researchers form drug discovery alliance with pharma giant

first_img By Jon CohenJun. 13, 2019 , 6:15 AM Weissman, a physicist who morphed into a protein-folding specialist, specializes in using CRISPR to construct large-scale probes of gene functions. “We don’t have the capability, the knowledge, or the resources to develop drugs,” he says. “I’m trying to understand what are the problems that [GSK is] facing and what are the tools that would really solve the problem. As a tool builder, my biggest fear is we build a bridge to nowhere.”In all, London-based GSK will fund 24 full-time UC researchers—only some of whom will come from Doudna’s and Weissman’s labs. GSK will contribute as many as 14 of its own employees. UC will own the intellectual property (IP) of any new tools invented in the lab, while GSK hopes to patent new drug targets. UC will receive a “financial benefit if a drug that requires licensed IP comes to market,” a GSK spokesperson says, noting that the exact terms are “confidential.”Hal Barron, GSK’s chief scientific officer, says 90% of genes still have opaque functions. He hopes that by using CRISPR to knock out or turn on genes in cells and animal models, the LGR will be able to double the number of genes with known functions. “Think about the impact of that as being able to develop twice as many drugs,” Barron says.Other academics who have had similar partnerships said they are useful, but can be tricky. “Overall, the model is great and the [CRISPR] space is ripe for innovation that’s not fundamental biology or chemistry but an engineering problem,” says UC San Francisco’s Jeffrey Bluestone, an immunologist who for the past 9 years has taken part in a collaboration between the school and Pfizer. The challenge, he says, is that there can be a “disconnect” when there’s a discovery about a potential drug that targets a disease not in the company’s portfolio.The Harvard Stem Cell Institute took part in a collaboration with GSK between 2008 and 2013 to develop new drug targets for regenerative medicine. “It was a really great interaction,” says Harvard stem cell biologist David Scadden, who notes it ended because GSK got out of the regenerative medicine business. “Having academics who are bilingual in terms of understanding how companies have to think as they develop products is a good thing,” he says.The lab, located at UC San Francisco’s Mission Bay campus, is already up and running. A new university-pharma alliance will use the genome editor CRISPR (red) to edit DNA (blue and yellow strands) in order to identify drug targets. Top CRISPR researchers at two University of California (UC) campuses have teamed up with pharmaceutical giant GlaxoSmithKline (GSK) to form a new laboratory in San Francisco that will exploit the genome editor to screen for new drugs.Drawing on a GSK commitment of $67 million over 5 years, UC Berkeley’s Jennifer Doudna, a co-inventor of the powerful CRISPR tool, and UC San Francisco’s Jonathan Weissman will select the academic talent to work in the new Laboratory for Genomics Research (LGR). “This is really, for us as academics, kind of a dream come true,” Doudna says.Although Doudna has already co-founded two CRISPR-related companies and co-runs the Innovative Genomics Institute with Weissman, she says the LGR “takes the not very interesting parts of the screening efforts out of the picture.” A friend who visited her lab a few years ago described it as “artisanal,” she recalls and wondered why they weren’t using more automation. “It was a nice way of saying that it seems really fusty,” Doudna says. She hopes the LGR will allow them to use “genome editing and CRISPR, in particular, as a tool to understand the causes of disease in a way that had really never been possible in the past.”center_img Meletios/shutterstock University of California CRISPR researchers form drug discovery alliance with pharma giantlast_img read more